Loading...
Loading...
Veraxa Biotech Holding AG
Veraxa Biotech Holding AG. Spoken Alpha tracks VRXA's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks VRXA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 100% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VRXA.
curl https://api.spokenalpha.com/v1/companies/VRXA| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.30 | $4.55 | +16.4% | +4.6% | +7.6% |
| Q4 FY2026 | $4.91 | $4.42 | +11.0% | +1.7% | +2.4% |
| Q3 FY2026 | $5.14 | $4.36 | +17.9% | +0.9% | -0.2% |
| Q2 FY2026 | $5.48 | $4.55 | +20.4% | +7.3% | +6.9% |
| Q1 FY2025 | $5.07 | $4.49 | +13.0% | +9.3% | +7.2% |
| Q4 FY2025 | $5.34 | $4.58 | +16.6% | +4.8% | +1.9% |
| Q3 FY2025 | $5.36 | $4.68 | +14.6% | +0.7% | -0.5% |
| Q2 FY2025 | $5.23 | $4.48 | +16.7% | +7.4% | +6.8% |
| Q1 FY2024 | $5.54 | $4.55 | +21.8% | +8.2% | +7.0% |
| Q4 FY2024 | $5.44 | $4.63 | +17.5% | +9.3% | +7.3% |